Jianhui Liu

Dr. Jianhui Liu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
WZWan-Jun Zhao
Wan-Jun Zhao
YBYang-Ping Bian
Yang-Ping Bian
QWQiu-Hui Wang
Qiu-Hui Wang
FYFei Yin
Fei Yin
LYLi Yin
Li Yin
JLJianhui Liu
Jianhui Liu

29 January 2023 in Phytomedicine
Verified
Journal Article
Closed access
JLJinfan Liu
Jinfan Liu
WLWeizhao Li
Weizhao Li
YBYangping Bian
Yangping Bian
XJXiaoqing Jiang
Xiaoqing Jiang
FZFuyun Zhu
Fuyun Zhu
JLJianhui Liu
Jianhui Liu

8 December 2022 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
YBYangping Bian
Yangping Bian
WLWeizhao Li
Weizhao Li
XJXiaoqing Jiang
Xiaoqing Jiang
FYFei Yin
Fei Yin
LYLi Yin
Li Yin
JLJianhui Liu
Jianhui Liu

12 October 2020 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
MLMin Liu
Min Liu
LWLujing Wang
Lujing Wang
XLXigan Li
Xigan Li
YWYucui Wu
Yucui Wu
FYFei Yin
Fei Yin
JLJianhui Liu
Jianhui Liu
Background: Trilobatin, a natural compound, has been found to exhibit anti-diabetic properties in high-fat diet (HFD) and streptozotocin (STZ) induced type 2 diabetic mice. But up to now no research has been reported on the effect of trilobatin on insulin resistance in peripheral tissues. Herein, we determined the effects of trilobatin on insulin resistance in palmitate-treated C2C12 myotubes and ob/ob mice. Methods: Male ob/ob mice (8-10 weeks) and same background C57BL/6 mice were used to evaluate the role of trilobatin on insulin resistance; protein expression and phosphorylation were measured by western blot; glucose uptake was determined a fluorescent test. Results: Treatment with trilobatin prevented palmitate-induced insulin resistance by enhancing glucose uptake and the phosphorylation of insulin resistance substrate 1 (IRS1) and protein Kinase B, (PKB/AKT), recovered the translocation of GLUT4 from cytoplasm to membrane, but preincubation with LY294002, an inhibitor of PI3K, blocked the effects of trilobatin on glucose uptake and the distribution of GLUT4 in C2C12 myotubes. Furthermore, administration with trilobatin for 4 weeks significantly improved insulin resistance by decreasing fasting blood glucose and insulin in serum, enhancing the phosphorylation of IRS1 and AKT, and recovering the expression and translocation of GLUT4 in ob/ob mice. Conclusions: IRS-AKT-GLUT4 signaling pathway might be involved in trilobatin ameliorating insulin resistance in skeletal muscle of obese animal models.

18 September 2019 in Molecules
Verified
Journal Article
Open access
PDF file
LWLujing Wang
Lujing Wang
MLMin Liu
Min Liu
FYFei Yin
Fei Yin
YWYuanqiang Wang
Yuanqiang Wang
XLXingan Li
Xingan Li
JLJianhui Liu
Jianhui Liu
Studies have indicated that Na+-d-glucose co-transporter (SGLT) inhibitors had anti-proliferative activity by attenuating the uptake of glucose in several tumor cell lines. In this study, the molecular docking showed that, trilobatin, one of the dihydrochalcones from leaves of Lithocarpus polystachyus Rehd., might be a novel inhibitor of SGLT1 and SGLT2, which evidently attenuated the uptake of glucose in vitro and in vivo. To our surprise, we observed that trilobatin did not inhibit, but promoted the proliferation of human hepatoblastoma HepG2 and Huh 7 cells when it was present at high concentrations. At the same time, incubation with high concentrations of trilobatin arrested the cell cycle at S phase in HepG2 cells. We also found that treatment with trilobatin had no significant effect on the expression of hepatitis B x-interacting protein (HBXIP) and hepatocyte nuclear factor (HNF)-4α, the two key regulators of hepatocyte proliferation. Taken together, although trilobatin worked as a novel inhibitor of SGLTs to attenuate the uptake of glucose, it also selectively induced the cell proliferation of HepG2 cells, suggesting that not all the SGLT inhibitors inhibited the proliferation of tumor cells, and further studies are needed to assess the anti-cancer potentials of new glucose-lowering agents.

20 December 2016 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
CLC. Y. Liu
C. Y. Liu
YHY. N. Hao
Y. N. Hao
FYFei Yin
Fei Yin
YZY. L. Zhang
Y. L. Zhang
JLJianhui Liu
Jianhui Liu